BR112017005113A2 - composto de fórmula geral (i), método para preparar um composto de fórmula geral (i), método para preparar um composto de fórmula geral (iv), composição farmacêutica para o tratamento de doenças relacionadas com atividades anormais de jak3 e/ou jak1 quinase, usos do composto, e usos da composição farmacêutica - Google Patents

composto de fórmula geral (i), método para preparar um composto de fórmula geral (i), método para preparar um composto de fórmula geral (iv), composição farmacêutica para o tratamento de doenças relacionadas com atividades anormais de jak3 e/ou jak1 quinase, usos do composto, e usos da composição farmacêutica

Info

Publication number
BR112017005113A2
BR112017005113A2 BR112017005113-3A BR112017005113A BR112017005113A2 BR 112017005113 A2 BR112017005113 A2 BR 112017005113A2 BR 112017005113 A BR112017005113 A BR 112017005113A BR 112017005113 A2 BR112017005113 A2 BR 112017005113A2
Authority
BR
Brazil
Prior art keywords
preparation
aromatic heterocyclic
kinase inhibitor
heterocyclic compounds
jak1 kinase
Prior art date
Application number
BR112017005113-3A
Other languages
English (en)
Chinese (zh)
Other versions
BR112017005113B1 (pt
Inventor
Lu Xianping
Yu Jindi
Yang Qianjiao
Li Zhibin
Pan Desi
Shan Song
Zhu Jiangfei
Wang Xianghui
Liu Xiangheng
Ning Zhiqiang
Original Assignee
Shenzhen Chipscreen Biosciences, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chipscreen Biosciences, Ltd. filed Critical Shenzhen Chipscreen Biosciences, Ltd.
Publication of BR112017005113A2 publication Critical patent/BR112017005113A2/pt
Publication of BR112017005113B1 publication Critical patent/BR112017005113B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

a presente invenção trata de uma aplicação de um composto que tem fórmula geral (i) como jak3 e/ou jak1 quinase e um método de preparação para o composto.
BR112017005113-3A 2014-09-16 2015-09-14 Composto de fórmula geral (i), método para preparar o composto de fórmula geral (i), método para preparar um composto de fórmula geral (iv), composição farmacêutica para o tratamento de doenças relacionadas com atividades anormais de jak3 e/ou jak1 quinases, uso do composto, e uso da composição farmacêutica BR112017005113B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410471468.9A CN105399685B (zh) 2014-09-16 2014-09-16 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用
CN201410471468.9 2014-09-16
PCT/CN2015/089499 WO2016041472A1 (zh) 2014-09-16 2015-09-14 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用

Publications (2)

Publication Number Publication Date
BR112017005113A2 true BR112017005113A2 (pt) 2018-01-23
BR112017005113B1 BR112017005113B1 (pt) 2023-02-14

Family

ID=55465491

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005113-3A BR112017005113B1 (pt) 2014-09-16 2015-09-14 Composto de fórmula geral (i), método para preparar o composto de fórmula geral (i), método para preparar um composto de fórmula geral (iv), composição farmacêutica para o tratamento de doenças relacionadas com atividades anormais de jak3 e/ou jak1 quinases, uso do composto, e uso da composição farmacêutica

Country Status (22)

Country Link
US (1) US10011571B2 (pt)
EP (1) EP3196194B1 (pt)
JP (1) JP6516305B2 (pt)
KR (1) KR101971887B1 (pt)
CN (1) CN105399685B (pt)
AU (1) AU2015317937B2 (pt)
BR (1) BR112017005113B1 (pt)
CA (1) CA2982881C (pt)
CY (1) CY1122423T1 (pt)
DK (1) DK3196194T3 (pt)
ES (1) ES2754403T3 (pt)
HK (1) HK1220975A1 (pt)
HR (1) HRP20191734T1 (pt)
HU (1) HUE045899T2 (pt)
LT (1) LT3196194T (pt)
PL (1) PL3196194T3 (pt)
PT (1) PT3196194T (pt)
RS (1) RS59467B1 (pt)
RU (1) RU2671195C2 (pt)
SI (1) SI3196194T1 (pt)
TW (1) TWI570109B (pt)
WO (1) WO2016041472A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026098A1 (en) * 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021088975A1 (zh) 2019-11-08 2021-05-14 深圳微芯生物科技股份有限公司 一种化合物用于预防或治疗移植物抗宿主病的用途
EP4066838A4 (en) * 2019-11-26 2023-12-27 Shenzhen Chipscreen Biosciences Co., Ltd. COMPOSITION CONTAINING AN AROMATIC HETEROCYCLIC COMPOUND IN AMORPHOUS FORM, PREPARATION METHOD AND USE THEREOF
CN111297866B (zh) * 2020-03-09 2021-04-02 深圳微芯生物科技股份有限公司 一种包含jak3/jak1/tbk1抑制剂和甲氨蝶呤的药物组合物及其用途
AU2022263067A1 (en) 2021-04-22 2023-11-02 Shenzhen Chipscreen Biosciences Co., Ltd. Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005547A (es) 2002-11-28 2005-07-26 Schering Ag Pirimidinas inhibidoras de chk, pdk y akt, su produccion y uso como agentes farmaceuticos.
CN101421250A (zh) * 2006-01-30 2009-04-29 埃克塞里艾克西斯公司 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物
EP2089369B1 (en) * 2006-10-19 2011-02-02 Rigel Pharmaceuticals, Inc. 2,4 -pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
CA2702647C (en) * 2007-01-31 2016-03-22 Ym Biosciences Australia Pty Ltd Thiopyrimidine-based compounds and uses thereof
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
ES2711249T3 (es) * 2008-06-27 2019-04-30 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
DE102009001438A1 (de) 2009-03-10 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
CN101906076B (zh) * 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
CN103073508B (zh) * 2011-10-25 2016-06-01 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法
CN104109127B (zh) * 2013-04-19 2019-11-05 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法

Also Published As

Publication number Publication date
PT3196194T (pt) 2019-11-18
BR112017005113B1 (pt) 2023-02-14
US10011571B2 (en) 2018-07-03
SI3196194T1 (sl) 2019-12-31
CN105399685A (zh) 2016-03-16
KR20170048593A (ko) 2017-05-08
HUE045899T2 (hu) 2020-01-28
EP3196194A4 (en) 2018-05-30
AU2015317937B2 (en) 2018-10-04
TW201612165A (en) 2016-04-01
JP6516305B2 (ja) 2019-05-22
US20170253566A1 (en) 2017-09-07
HK1220975A1 (zh) 2017-05-19
LT3196194T (lt) 2019-10-10
HRP20191734T1 (hr) 2019-12-13
AU2015317937A1 (en) 2017-04-27
ES2754403T3 (es) 2020-04-17
TWI570109B (zh) 2017-02-11
JP2017527625A (ja) 2017-09-21
RU2017112299A (ru) 2018-10-17
EP3196194B1 (en) 2019-08-07
CA2982881C (en) 2020-02-25
RS59467B1 (sr) 2019-11-29
RU2017112299A3 (pt) 2018-10-17
CN105399685B (zh) 2018-05-22
CY1122423T1 (el) 2021-01-27
PL3196194T3 (pl) 2020-01-31
EP3196194A1 (en) 2017-07-26
RU2671195C2 (ru) 2018-10-30
CA2982881A1 (en) 2016-03-24
KR101971887B1 (ko) 2019-04-25
DK3196194T3 (da) 2019-10-28
WO2016041472A1 (zh) 2016-03-24

Similar Documents

Publication Publication Date Title
CY1120988T1 (el) Παρεμποδιστες διαρυλ κινασης
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
NI201800128A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
SG10201809518QA (en) Processes of preparing a jak1 inhibitor and new forms thereto
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
UY35951A (es) HETEROARILOS y USOS DE ESTOS
BR112013003388A2 (pt) sal de besilato de um inibidor de btk
BR112016014412A2 (pt) Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
BR112016024533A2 (pt) derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
CR20180352A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2016009352A (es) Inhibidores de quinasa a base de quinolina.
BR112017005113A2 (pt) composto de fórmula geral (i), método para preparar um composto de fórmula geral (i), método para preparar um composto de fórmula geral (iv), composição farmacêutica para o tratamento de doenças relacionadas com atividades anormais de jak3 e/ou jak1 quinase, usos do composto, e usos da composição farmacêutica
UY37017A (es) Inhibidores aza-bencimidazol de pad4
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
MX2016009355A (es) Inhibidores de aril lactama cinasa.
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/09/2015, OBSERVADAS AS CONDICOES LEGAIS